Condition: Cardiac Toxicity · Lung Cancer Stage III · Lung Cancer Stage II · Sponsor: Odense University Hospital
Patients with loco-regional NSCLC planned for curative treatment with chemoradiotherapy will be invited to participate in a prospective study; besides routine treatment, the patients will be followed with an ECG and cardiac MR for at least two years after radiotherapy treatment.
This description comes directly from the study's public registry record.
Agon AO Olloni, MD · 42206617 · agon.olloni@rsyd.dk
Always discuss trial participation with your own doctor first.
| Odense University Hospital | Odense C, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05258448